DME

The ERG is a game changer for patients with diabetes.

Sherrol A. Reynolds, OD, FAAO, shares highlights from her discussion, "The OD's role in addressing silent killers: diabetes, hypertension, and dyslipidemia," which she presented during this year's American Academy of Optometry annual meeting.

Anthony DeWilde, OD, FAAO, shares highlights from his AAOpt presentation, "Anti-VEGF and the eye: Past, present and future."

World Sight Day is upon us and RestoringVision has issued a lofty but doable goal: help solve the global vision crisis.

In honor of World Sight Day, optometrists and ophthalmologists reflect on what today means to them.

The data analysis showed that the macular thickness decreased across all time periods and in all macular regions for all tertiles.

OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone that has the potential to be the first topical eye drop and non-invasive treatment for DME.

Ashley Tucker, OD, FAAO, FSLS, Dipl ABO, shares highlights from her discussion titled, "Myopia management: past, present, and future," presented during this year's 115th annual SCOPA meeting.

Leo P. Semes, OD, FAAO, highlights his presentation on "Artificial intelligence and telemedicine," presented during the 115th annual SCOPA meeting.

Leo P. Semes, OD, FAAO, discusses his presentation on, "A new look at AMD," during the South Carolina Optometric Physicians Association's annual meeting.

Latest data from phase 3 studies finds increased effects over time with intravitreal pegcetacoplan for geographic atrophy secondary to age-related macular degeneration.

New DME treatments aim to extend time between intravitreal injections.

A recent clinical trial from the DRCR Retina Network examined a stepped regimen of anti-VEGF drugs bevacizumab and aflibercept.

IBI324 is a potential first-in-class ophthalmic recombinant human anti-VEGF-A and anti-Ang-2 bispecific antibody.

Proper screenings, treatment, management needed for this increasingly prevalent disease.

Ranibizumab-eqrn will offer greater treatment access and choice for patients, payors, and providers in the US.

Advancements enable better diagnosis, treatment of patients.

A decade after the conclusion of the NIH-funded AREDS2 study, researchers found that the AREDS2 formula also reduces the risk of lung cancer.

All data were collected in the Fight Retinal Blindness! Registry.

This is the second FDA-approved indication for BEOVU; it was initially approved in 2019 for the treatment of wet AMD.

A look at the latest developments in retinal disease, including clinical trials and advanced therapies.

Oxurion NV finds insufficient evidence of efficacy on key clinical endpoints for THR-687 in Part A of the INTEGRAL phase 2 trial; focus will now turn to an alternative candidate and trial.

Investigators report a correlation between the risk of 5-letter visual acuity (VA) loss at 24 months for eyes with clinically significant diabetic macular edema (CSDME) and good VA initially treated and eyes that were initially observed in routine clinical practice.

Researchers found that patients with nAMD lost vision as a result of the lockdown and reduced number of treatments during the COVID-19 pandemic.

Elevatum was created as a phase 4, multicenter, open-label, single-arm trial to specifically study Vabysmo (faricimab-svoa) in these underrepresented populations.